Project cooperationUpdated on 9 April 2026
ASC1R
About
ASC1R is an oligonucleotide-based therapeutic developed on the ESiNAR-X platform, targeting the SARS-CoV-2 RNA virus and intended for critically ill patients requiring intensive care to rapidly inhibit viral replication.
Status: Transitioning into Phase I clinical development, alongside GMP production of the drug substance and finished drug product.
We are seeking investments and partnerships to support the execution of clinical trials.
Similar opportunities
Partnership
Do Youn Chun
Chief Technical Officer at AT-31 BIO Inc.
Daegu, South Korea
Partnership
Enhancing antitumoral drugs with our "smart antitumoral nanovectors"
Ana Bouchet
CEO at Lifesome Therapeutics
MADRID, Spain
Project cooperation
Stefano Brianza
Owner at Biomech Innovations AG
Nidau, Switzerland